CASP3 and neuroblastoma: We also assessed the impact of the combination of trametinib and ganitumab on apoptosis in RAS-altered neuroblastoma cells using both a luminescence-based assessment of caspase 3/7 activity (Figure 3C) and a flow cytometric assessment of annexin positivity (Figure 3D).